Class / Patent application number | Description | Number of patent applications / Date published |
514445000 | Chalcogen bonded directly to ring carbon of the hetero ring | 17 |
20080300295 | Inhibitors of Ccr9 Activity - Compounds of formula I, wherein one of R | 12-04-2008 |
20080312313 | Inhibitors of Ccr9 Activity -
A compound of formula (I), wherein the residues have various meanings, useful as pharmaceuticals. | 12-18-2008 |
20090005435 | Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same - A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula (II), wherein R | 01-01-2009 |
20090023801 | INHIBITORS OF BETA AMYLOID PRODUCTION - Novel sulfonamide compounds useful in the treatment of conditions related to the production of beta-amyloid are described, as are routes to their preparation. The sulfonamide compounds are of the following structure, wherein R | 01-22-2009 |
20090093536 | PHARMACEUTICAL COMPOSITION COMPRISING THIACREMONONE FOR PREVENTING OR TREATING CANCER - The present invention relates to an anti-cancer composition, which comprises a sulfur-containing compound thiacremonone as an active ingredient. The active ingredient induces the death of cancer cells by apoptosis through the action of specific inhibition of the activity of NF-κB. The composition can be effectively used in the treatment or prevention of cancer. | 04-09-2009 |
20090124684 | Stimulation Of CPT-1 As A Means To Reduce Weight - This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level. | 05-14-2009 |
20100048684 | EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF - The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway. | 02-25-2010 |
20100120901 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME - A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R | 05-13-2010 |
20100160423 | SMALL MOLECULE ANTAGONISTS OF BACTERIAL QUORUM-SENSING RECEPTORS - A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote | 06-24-2010 |
20100168218 | METHOD OF REDUCING FOOD INTAKE - A method of decreasing the food intake of a subject, comprising the administration of a compound which increases FAO, where the compound does not act in the central nervous system to decrease appetite, where the compound is not a fatty acid, or an NPY-inhibitor, or an FAS inhibitor. | 07-01-2010 |
20110077290 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS - A compound represented by the formula (1): | 03-31-2011 |
20110172298 | INDICATION OF USE OF ERDOSTEINE AS ANTIDOTE IN A LARGE NUMBER OF INTOXICATIONS, ESPECIALLY IN HEAVY METALS LIKE LEAD OR MERCURY, AND PARACETAMOL - Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol. Indication of use of erdosteine as prophylaxis for intoxications. Erdosteine can be administered per os or intravenous, using a solution obtained with sodium hydrogen carbonate and bidistilled water. | 07-14-2011 |
20110263691 | METHODS CONCERNING PPAR DELTA AND ANTAGONISTS THEREOF - Non-human animals which overexpress PPARd or which express transgenic PPARd are useful as models for inflammatory skin conditions such as psoriasis. Test substances can be screened to assess their suitability for the treatment of inflammatory skin conditions such as psoriasis. Methyl 3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate can be administered topically for the prevention or treatment of psoriasis. | 10-27-2011 |
20130303599 | IRE1ALPHA ENDONUCLEASE SPECIFIC INHIBITOR WITH CYTOTOXIC ACTIVITY - Activation of the adaptive Ire1-XBP1 pathway has been identified in many solid tumors and hematological malignancies, including multiple myeloma (MM). What is disclosed is STF-083010, a novel small molecule inhibitor of Ire1. STF-083010 inhibited Ire1 endonuclease activity, without affecting its kinase activity, after ER stress both in vitro and in vivo. Treatment with STF-083010 showed significant anti-myeloma activity in model human MM xenografts. Similarly, STF-083010 was preferentially toxic to freshly isolated human CD138(+) MM cells when compared to other similarly isolated cell populations. The identification of this novel Ire1 inhibitor supports the hypothesis that the Ire1-XBP1 axis is a promising target for anti-cancer therapy, especially in the context of multiple myeloma. | 11-14-2013 |
20140243401 | METHODS OF SCREENING COMPOUNDS THAT ARE CYTOTOXIC TO TUMOR CELLS AND METHODS OF TREATING TUMOR CELLS USING SUCH COMPOUND - The invention relates to methods of screening to find compounds that are cytotoxic to tumor cells and methods of treating tumor cells using these compounds. In particular, the invention relates to methods of screening for compounds that inhibit mammalian mitochondrial fatty acid synthase (mmFAS) and methods of treating tumor cells using mmFAS inhibitors. This invention also provides methods for inhibiting or preventing cancer cell survival by the administration of mitochondrial fatty acid synthase (FAS) inhibitors. Specifically, this invention describes a method for prohibiting or delaying the development of cancer, the growth of cancer or invasion of cancer from pre-malignant (noninvasive) lesions, or metastasis of cancer based upon the findings that this method compromises energy balance in cancer cells, in turn compromising their basic functions and causing their cell death. Compositions of matter containing mitochondrial FAS inhibition activity are also provided, as well as applications based upon the requisite role of mitochondrial FAS in cancer cell homeostasis. | 08-28-2014 |
20140275232 | SMALL MOLECULE ANTAGONISTS OF BACTERIAL QUORUM-SENSING RECEPTORS - A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote | 09-18-2014 |
20150018411 | COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES - The present invention concerns substances which act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and which can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of this invention act as inhibitors of PPAR beta/delta receptors. | 01-15-2015 |